Abstract
BACKGROUND: Cardiac amyloidosis represents an archetypal form of restrictive heart disease, characterized by profound diastolic dysfunction. As ejection fraction is preserved until the late stage of the disease, the majority of patients do fulfill the definition of diastolic heart failure, that is, heart failure with preserved ejection fraction (HFpEF). In another clinical model of HFpEF, that is, pressure-overload hypertrophy, depressed midwall fractional shortening (mFS) has been shown to be a powerful prognostic factor. OBJECTIVE AND METHODS: To assess the potential prognostic role of mFS in cardiac light-chain amyloidosis with preserved ejection fraction, we enrolled 221 consecutive untreated patients, in whom a first diagnosis of cardiac light-chain amyloidosis was concluded between 2008 and 2010. HFpEF was present in 181 patients. Patients in whom cardiac involvement was excluded served as controls (n=121). Prognosis was assessed after a median follow-up of 561 days. RESULTS: When compared with light-chain amyloidosis patients without myocardial involvement, cardiac light-chain amyloidosis was characterized by increased wall thickness (P
| Original language | English |
|---|---|
| Pages (from-to) | 1121-1131 |
| Number of pages | 11 |
| Journal | Journal of Hypertension |
| Volume | 32 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- amyloidosis
- midwall fractional shortening
- prognosis
- systolic function
ASJC Scopus subject areas
- Internal Medicine
- Physiology
- Cardiology and Cardiovascular Medicine
Cite this
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. / Perlini, Stefano; Salinaro, Francesco; Musca, Francesco; Mussinelli, Roberta; Boldrini, Michele; Raimondi, Ambra; Milani, Paolo; Foli, Andrea; Cappelli, Francesco; Perfetto, Federico; Palladini, Giovanni; Rapezzi, Claudio; Merlini, Giampaolo.
In: Journal of Hypertension, Vol. 32, No. 5, 2014, p. 1121-1131.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis
AU - Perlini, Stefano
AU - Salinaro, Francesco
AU - Musca, Francesco
AU - Mussinelli, Roberta
AU - Boldrini, Michele
AU - Raimondi, Ambra
AU - Milani, Paolo
AU - Foli, Andrea
AU - Cappelli, Francesco
AU - Perfetto, Federico
AU - Palladini, Giovanni
AU - Rapezzi, Claudio
AU - Merlini, Giampaolo
PY - 2014
Y1 - 2014
N2 - BACKGROUND: Cardiac amyloidosis represents an archetypal form of restrictive heart disease, characterized by profound diastolic dysfunction. As ejection fraction is preserved until the late stage of the disease, the majority of patients do fulfill the definition of diastolic heart failure, that is, heart failure with preserved ejection fraction (HFpEF). In another clinical model of HFpEF, that is, pressure-overload hypertrophy, depressed midwall fractional shortening (mFS) has been shown to be a powerful prognostic factor. OBJECTIVE AND METHODS: To assess the potential prognostic role of mFS in cardiac light-chain amyloidosis with preserved ejection fraction, we enrolled 221 consecutive untreated patients, in whom a first diagnosis of cardiac light-chain amyloidosis was concluded between 2008 and 2010. HFpEF was present in 181 patients. Patients in whom cardiac involvement was excluded served as controls (n=121). Prognosis was assessed after a median follow-up of 561 days. RESULTS: When compared with light-chain amyloidosis patients without myocardial involvement, cardiac light-chain amyloidosis was characterized by increased wall thickness (P
AB - BACKGROUND: Cardiac amyloidosis represents an archetypal form of restrictive heart disease, characterized by profound diastolic dysfunction. As ejection fraction is preserved until the late stage of the disease, the majority of patients do fulfill the definition of diastolic heart failure, that is, heart failure with preserved ejection fraction (HFpEF). In another clinical model of HFpEF, that is, pressure-overload hypertrophy, depressed midwall fractional shortening (mFS) has been shown to be a powerful prognostic factor. OBJECTIVE AND METHODS: To assess the potential prognostic role of mFS in cardiac light-chain amyloidosis with preserved ejection fraction, we enrolled 221 consecutive untreated patients, in whom a first diagnosis of cardiac light-chain amyloidosis was concluded between 2008 and 2010. HFpEF was present in 181 patients. Patients in whom cardiac involvement was excluded served as controls (n=121). Prognosis was assessed after a median follow-up of 561 days. RESULTS: When compared with light-chain amyloidosis patients without myocardial involvement, cardiac light-chain amyloidosis was characterized by increased wall thickness (P
KW - amyloidosis
KW - midwall fractional shortening
KW - prognosis
KW - systolic function
UR - http://www.scopus.com/inward/record.url?scp=84898406800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898406800&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000000120
DO - 10.1097/HJH.0000000000000120
M3 - Article
C2 - 24509117
AN - SCOPUS:84898406800
VL - 32
SP - 1121
EP - 1131
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 5
ER -